​Aminocaproic acid - CAS 60-32-2
Catalog number: 60-32-2
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C6H13NO2
Molecular Weight:
131.17
COA:
Inquire
Targets:
Others
Description:
Aminocaproic acid is a derivative and analogue of the amino acid lysine, which makes it an effective inhibitor for enzymes that bind that particular residue. Such enzymes include proteolytic enzymes like plasmin, the enzyme responsible for fibrinolysis.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
MSDS:
Inquire
1.Study on mutual interactions and electronic structures of hyaluronan with Lysine, 6-Aminocaproic acid and Arginine.
Chytil M1, Trojan M2, Kovalenko A3. Carbohydr Polym. 2016 May 20;142:8-15. doi: 10.1016/j.carbpol.2016.01.035. Epub 2016 Jan 18.
Interactions between polyelectrolytes and oppositely charged surfactants have been in a great interest for several decades, yet the conventional surfactants may cause a problem in medical applications. Interactivity between polysaccharide hyaluronan (HA) and amino acids Lysine, 6-Aminocaproic acid (6-AcA), and Arginine as an alternative system is reported. The interactions were investigated by means of rheology and electric conductance and the electronic structures were explored by the density functional theory (DFT). Lysine exhibits the strongest interaction of all, which was manifested, e.g. by nearly 6-time drop of the initial viscosity comparing with only 1.3-time lower value in the case of 6-AcA. Arginine interaction with HA was surprisingly weaker in terms of viscosity than that of Lysine due to a lower and delocalized charge density on its guanidine group. According to the DFT calculations, the binding of Lysine to HA was found to be more flexible, while Arginine creates more rigid structure with HA.
2.Preoperative management of factor XI deficiency with therapeutic plasma exchange: A case report and literature review.
Pagano MB1, Konkle BA2, Wu Y3, Josephson N4. J Clin Apher. 2015 Dec 18. doi: 10.1002/jca.21442. [Epub ahead of print]
Patients with factor XI deficiency may have bleeding complications during surgery. Because bleeding severity and factor levels correlate poorly, factor replacement needs to be personalized based on bleeding history and type of procedure. We report a 65-year-old male with factor XI deficiency (7 IU dL-1 ) who presented before scheduled hip arthroplasty. He had a history of total hip arthroplasty complicated by bleeding, delayed healing and prosthesis removal, despite receiving prophylactic treatment with plasma infusion. For the current surgery a factor XI ≥50 IU dL-1 level was targeted. The calculated plasma infusion needed to achieve this goal was 3100 mL (14 U). Because of concerns about circulatory overload and inability to achieve target by simple infusion, prophylactic treatment with therapeutic plasma exchange (TPE) was requested. TPE was performed the morning before the surgery, using 100% plasma as replacement fluid (3912 mL of plasma), and a positive fluid balance of 631 mL.
3.Aminocaproic acid for the management of bleeding in patients on extracorporeal membrane oxygenation: Four adult case reports and a review of the literature.
Buckley LF1, Reardon DP2, Camp PC3, Weinhouse GL4, Silver DA5, Couper GS6, Connors JM7. Heart Lung. 2016 Feb 19. pii: S0147-9563(16)00012-1. doi: 10.1016/j.hrtlng.2016.01.011. [Epub ahead of print]
BACKGROUND: Extracorporeal membrane oxygenation (ECMO) is associated with a significant risk of bleeding and thrombosis. Despite high rates of bleeding and bleeding-related mortality in patients on ECMO, there is little evidence available to guide clinicians in the management of ECMO-associated bleeding.
4.Epsilon-Aminocaproic Acid Has No Association With Thromboembolic Complications, Renal Failure, or Mortality after Liver Transplantation.
Nicolau-Raducu R1, Ku TC2, Ganier DR3, Evans BM3, Koveleskie J3, Daly WJ Jr3, Fish B3, Cohen AJ4, Reichman TW4, Bohorquez HE4, Bruce DS4, Carmody IC4, Loss GE4, Gitman M5, Marshall T3, Nossaman BD3. J Cardiothorac Vasc Anesth. 2015 Dec 3. pii: S1053-0770(15)00964-7. doi: 10.1053/j.jvca.2015.12.003. [Epub ahead of print]
OBJECTIVES: To examine the role of epsilon-aminocaproic acid (EACA) administered after reperfusion of the donor liver in the incidences of thromboembolic events and acute kidney injury within 30 days after orthotopic liver transplantation. One-year survival rates between the EACA-treated and EACA-nontreated groups also were examined.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


CAS 236395-14-5 Eslicarbazepine Acetate

Eslicarbazepine Acetate
(CAS: 236395-14-5)

Eslicarbazepine acetate, (BIA 2-093), is a promising antiepileptic drug structurally related to Carbamazepine and Oxcarbazepine.

CAS 1449208-36-9 Ensemble Compound 159

Ensemble Compound 159
(CAS: 1449208-36-9)

Ensemble Compound 159 is a peptide inhibitor of IL-17A that binds to IL-17A and/or inhibits formation of the IL-17A–IL-17RA complex via an ELISA assay, an HT29-...

Cenerimod
(CAS: 1262414-04-9)

Cenerimod is an active Lysosphingolipid receptor agonist originated by Actelion Pharmaceuticals and EC50 value is 2.7 nM. It is a S1P1/EDG1 receptor agonist and...

CAS 105956-99-8 Clinafloxacin hydrochloride

Clinafloxacin hydrochloride
(CAS: 105956-99-8)

Clinafloxacin hydrochloride is a novel fluoroquinolone antimicrobial agent as a potent intraphagocytic bactericidal agent. It displays broad-spectrum antibacter...

CAS 2415-24-9 Catalpol

Catalpol
(CAS: 2415-24-9)

Catalpol can be extracted from the herb of Rehmannia glutinosa (Gaert.) Libosch. ex Fisch. et Mey. It primary function is to stimulate the production of adrenal...

AT-1459
(CAS: 294658-50-7)

AT-1459 is a novel, direct thrombin inhibitor with antithrombotic efficacy (Ki = 4.9 nM).

Fumarate hydratase-IN-1
(CAS: 1644060-37-6)

Fumarate hydratase-IN-1, an enzyme of the TCA cycle, identified as the principal pharmacological target.

CAS 1641-17-4 Mexenone

Mexenone
(CAS: 1641-17-4)

Mexenone, the derivative of benzophenone, is a sunscreening agent.

CAS 86696-86-8 Tenilsetam

Tenilsetam
(CAS: 86696-86-8)

Tenilsetam is an endonuclease modulator, also a nootropic agent and advanced glycation end product (AGE) inhibitor with the potential to treat Alzheimer's disea...

CAS 1509-34-8 L-Allo-isoleucine

L-Allo-isoleucine
(CAS: 1509-34-8)

L-Allo-isoleucine, an amino acid compound, has been found to be probably significant in the study of modulating of blood sugar.

CAS 120938-72-9 LY 243670

LY 243670
(CAS: 120938-72-9)

LY 243670 is a bio-active molecular, but detailed information were not published yet.

CAS 167074-97-7 10-Oxo Docetaxel

10-Oxo Docetaxel
(CAS: 167074-97-7)

A novel taxoid having remarkable anti-tumor properties. Docetaxel intermediate. This product is unstable in solution, epimerize.

CAS 432020-20-7 SMI 481

SMI 481
(CAS: 432020-20-7)

SMI 481 is a small-molecule inhibitor (SMI) of the yeast phosphatidylinositol transfer proteins (PITP) Sec14 (IC50 values of 211 nM and 2.87 μM for Sec14 mediat...

CAS 102-29-4 Resorcinol monoacetate

Resorcinol monoacetate
(CAS: 102-29-4)

Resorcinol monoacetate, an analogue of Resorcinol,could be widely used as an active ingredient in many drug products for the treatment of skin disorders.

CAS 1093069-32-9 JNJ-39327041

JNJ-39327041
(CAS: 1093069-32-9)

JNJ-39327041 is a bio-active chemical compound.

BMS 214428
(CAS: 216508-01-9)

BMS 214428 has antineoplastic effect.

CAS 1140525-25-2 SB290157 trifluoroacetate

SB290157 trifluoroacetate
(CAS: 1140525-25-2)

SB290157 trifluoroacetate is selective, high affinity, competitive C3areceptor antagonist (IC50= 200 nM) suitable for use in animal models of inflammation.

CGP 76030
(CAS: 497152-38-2)

CGP76030 is a ual-specific Src and Abl kinase inhibitor, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases.

GNE-3500
(CAS: 1537859-24-7)

GNE-3500 has been found to be a Retinoic acid receptor-related Orphan receptor C agonist that could be probably significant in studies of some inflammatory dise...

CAS 370893-06-4 Ancriviroc

Ancriviroc
(CAS: 370893-06-4)

Ancriviroc, an oximino-piperidino-piperidine-amide, is a CCR5 receptor antagonist.

Chemical Structure

CAS 60-32-2 ​Aminocaproic acid

Quick Inquiry

Verification code

Featured Items